Consumption of garlic not associated decreased risk of colorectal cancer
the ONA take:
According to a new study published in World Journal of Gastroenterology, researchers have found that the consumption of raw or cooked garlic or garlic supplements is not significantly linked with a decreased risk for developing colorectal cancer.
For the study, researchers sought to conduct a meta-analysis of trials that prospectively studied the association between garlic or garlic supplement consumption and colorectal cancer. They identidfied five prospective studies that looked at either the consumption of garlic, whether raw or cooked, or garlic supplements and its association with the development of colorectal cancer.
Relative risks with 95% confidence intervals were calculated. Unlike a previous meta-analysis that did identify a significant association between raw or cooked garlic and cancer, this study did not. Researchers found a relative risk of 1.06 (95% CI: 0.95 - 1.19) between consumption of raw or cooked garlic and risk of colorectal cancer.
In addition, the relative risk between garlic supplements and risk of cancer was 1.12 (95% CI: 0.96 - 1.31). Researchers did find, however, non-significant protective benefit of garlic supplements against colorectal cancer in women (RR = 0.84, 95 CI: 0.64 - 1.11), but the opposite effect in men (RR = 1.24; 95% CI: 0.96 - 1.59).
Consumption of raw or cooked garlic or garlic supplements not significantly linked.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|